FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy

Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence. Stem phenotypes involving Wnt-β-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere for...

Full description

Bibliographic Details
Main Authors: Carlos J Diaz Osterman, Duygu Ozmadenci, Elizabeth G Kleinschmidt, Kristin N Taylor, Allison M Barrie, Shulin Jiang, Lisa M Bean, Florian J Sulzmaier, Christine Jean, Isabelle Tancioni, Kristen Anderson, Sean Uryu, Edward A Cordasco, Jian Li, Xiao Lei Chen, Guo Fu, Marjaana Ojalill, Pekka Rappu, Jyrki Heino, Adam M Mark, Guorong Xu, Kathleen M Fisch, Vihren N Kolev, David T Weaver, Jonathan A Pachter, Balázs Győrffy, Michael T McHale, Denise C Connolly, Alfredo Molinolo, Dwayne G Stupack, David D Schlaepfer
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2019-09-01
Series:eLife
Subjects:
Online Access:https://elifesciences.org/articles/47327
id doaj-7193db572cdc40948c8a07915a6afd96
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Carlos J Diaz Osterman
Duygu Ozmadenci
Elizabeth G Kleinschmidt
Kristin N Taylor
Allison M Barrie
Shulin Jiang
Lisa M Bean
Florian J Sulzmaier
Christine Jean
Isabelle Tancioni
Kristen Anderson
Sean Uryu
Edward A Cordasco
Jian Li
Xiao Lei Chen
Guo Fu
Marjaana Ojalill
Pekka Rappu
Jyrki Heino
Adam M Mark
Guorong Xu
Kathleen M Fisch
Vihren N Kolev
David T Weaver
Jonathan A Pachter
Balázs Győrffy
Michael T McHale
Denise C Connolly
Alfredo Molinolo
Dwayne G Stupack
David D Schlaepfer
spellingShingle Carlos J Diaz Osterman
Duygu Ozmadenci
Elizabeth G Kleinschmidt
Kristin N Taylor
Allison M Barrie
Shulin Jiang
Lisa M Bean
Florian J Sulzmaier
Christine Jean
Isabelle Tancioni
Kristen Anderson
Sean Uryu
Edward A Cordasco
Jian Li
Xiao Lei Chen
Guo Fu
Marjaana Ojalill
Pekka Rappu
Jyrki Heino
Adam M Mark
Guorong Xu
Kathleen M Fisch
Vihren N Kolev
David T Weaver
Jonathan A Pachter
Balázs Győrffy
Michael T McHale
Denise C Connolly
Alfredo Molinolo
Dwayne G Stupack
David D Schlaepfer
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
eLife
beta-catenin
focal adhesion kinase FAK
ovarian cancer
platinum chemotherapy
pluripotency
tumorspheres
author_facet Carlos J Diaz Osterman
Duygu Ozmadenci
Elizabeth G Kleinschmidt
Kristin N Taylor
Allison M Barrie
Shulin Jiang
Lisa M Bean
Florian J Sulzmaier
Christine Jean
Isabelle Tancioni
Kristen Anderson
Sean Uryu
Edward A Cordasco
Jian Li
Xiao Lei Chen
Guo Fu
Marjaana Ojalill
Pekka Rappu
Jyrki Heino
Adam M Mark
Guorong Xu
Kathleen M Fisch
Vihren N Kolev
David T Weaver
Jonathan A Pachter
Balázs Győrffy
Michael T McHale
Denise C Connolly
Alfredo Molinolo
Dwayne G Stupack
David D Schlaepfer
author_sort Carlos J Diaz Osterman
title FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
title_short FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
title_full FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
title_fullStr FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
title_full_unstemmed FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
title_sort fak activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy
publisher eLife Sciences Publications Ltd
series eLife
issn 2050-084X
publishDate 2019-09-01
description Gene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence. Stem phenotypes involving Wnt-β-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere formation are here associated with spontaneous gains in Kras, Myc and FAK (KMF) genes in a new aggressive murine model of ovarian cancer. Adhesion-independent FAK signaling sustained KMF and human tumorsphere proliferation as well as resistance to cisplatin cytotoxicity. Platinum-resistant tumorspheres can acquire a dependence on FAK for growth. Accordingly, increased FAK tyrosine phosphorylation was observed within HGSOC patient tumors surviving neo-adjuvant chemotherapy. Combining a FAK inhibitor with platinum overcame chemoresistance and triggered cell apoptosis. FAK transcriptomic analyses across knockout and reconstituted cells identified 135 targets, elevated in HGSOC, that were regulated by FAK activity and β-catenin including Myc, pluripotency and DNA repair genes. These studies reveal an oncogenic FAK signaling role supporting chemoresistance.
topic beta-catenin
focal adhesion kinase FAK
ovarian cancer
platinum chemotherapy
pluripotency
tumorspheres
url https://elifesciences.org/articles/47327
work_keys_str_mv AT carlosjdiazosterman fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT duyguozmadenci fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT elizabethgkleinschmidt fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT kristinntaylor fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT allisonmbarrie fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT shulinjiang fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT lisambean fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT florianjsulzmaier fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT christinejean fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT isabelletancioni fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT kristenanderson fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT seanuryu fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT edwardacordasco fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT jianli fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT xiaoleichen fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT guofu fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT marjaanaojalill fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT pekkarappu fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT jyrkiheino fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT adammmark fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT guorongxu fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT kathleenmfisch fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT vihrennkolev fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT davidtweaver fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT jonathanapachter fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT balazsgyorffy fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT michaeltmchale fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT denisecconnolly fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT alfredomolinolo fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT dwaynegstupack fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
AT daviddschlaepfer fakactivitysustainsintrinsicandacquiredovariancancerresistancetoplatinumchemotherapy
_version_ 1721458989890273280
spelling doaj-7193db572cdc40948c8a07915a6afd962021-05-05T17:53:37ZengeLife Sciences Publications LtdeLife2050-084X2019-09-01810.7554/eLife.47327FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapyCarlos J Diaz Osterman0Duygu Ozmadenci1Elizabeth G Kleinschmidt2Kristin N Taylor3Allison M Barrie4Shulin Jiang5Lisa M Bean6Florian J Sulzmaier7Christine Jean8Isabelle Tancioni9Kristen Anderson10Sean Uryu11Edward A Cordasco12Jian Li13Xiao Lei Chen14Guo Fu15Marjaana Ojalill16Pekka Rappu17https://orcid.org/0000-0002-5068-2842Jyrki Heino18Adam M Mark19Guorong Xu20Kathleen M Fisch21Vihren N Kolev22David T Weaver23Jonathan A Pachter24Balázs Győrffy25Michael T McHale26Denise C Connolly27Alfredo Molinolo28Dwayne G Stupack29https://orcid.org/0000-0003-4396-5745David D Schlaepfer30https://orcid.org/0000-0003-4814-9210Department of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesState Key Laboratory of Cellular Stress Biology, Innovation Center for Cellular Signaling Network, School of Life Sciences, Xiamen University, Xiamen, ChinaState Key Laboratory of Cellular Stress Biology, Innovation Center for Cellular Signaling Network, School of Life Sciences, Xiamen University, Xiamen, ChinaState Key Laboratory of Cellular Stress Biology, Innovation Center for Cellular Signaling Network, School of Life Sciences, Xiamen University, Xiamen, ChinaDepartment of Biochemistry, University of Turku, Turku, FinlandDepartment of Biochemistry, University of Turku, Turku, FinlandDepartment of Biochemistry, University of Turku, Turku, FinlandDepartment of Medicine, UCSD Center for Computational Biology & Bioinformatics, La Jolla, United StatesDepartment of Medicine, UCSD Center for Computational Biology & Bioinformatics, La Jolla, United StatesDepartment of Medicine, UCSD Center for Computational Biology & Bioinformatics, La Jolla, United StatesVerastem Oncology, Needham, United StatesVerastem Oncology, Needham, United StatesVerastem Oncology, Needham, United StatesInstitute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary; 2nd Department of Pediatrics, Semmelweis University, Budapest, HungaryDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesFox Chase Cancer Center, Philadelphia, United StatesDepartment of Pathology, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Moores UCSD Cancer Center, La Jolla, United StatesGene copy number alterations, tumor cell stemness, and the development of platinum chemotherapy resistance contribute to high-grade serous ovarian cancer (HGSOC) recurrence. Stem phenotypes involving Wnt-β-catenin, aldehyde dehydrogenase activities, intrinsic platinum resistance, and tumorsphere formation are here associated with spontaneous gains in Kras, Myc and FAK (KMF) genes in a new aggressive murine model of ovarian cancer. Adhesion-independent FAK signaling sustained KMF and human tumorsphere proliferation as well as resistance to cisplatin cytotoxicity. Platinum-resistant tumorspheres can acquire a dependence on FAK for growth. Accordingly, increased FAK tyrosine phosphorylation was observed within HGSOC patient tumors surviving neo-adjuvant chemotherapy. Combining a FAK inhibitor with platinum overcame chemoresistance and triggered cell apoptosis. FAK transcriptomic analyses across knockout and reconstituted cells identified 135 targets, elevated in HGSOC, that were regulated by FAK activity and β-catenin including Myc, pluripotency and DNA repair genes. These studies reveal an oncogenic FAK signaling role supporting chemoresistance.https://elifesciences.org/articles/47327beta-cateninfocal adhesion kinase FAKovarian cancerplatinum chemotherapypluripotencytumorspheres